Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of different doses of SAL0139 tablets in hyperlipidemia
CTR20262644Phase 2Active
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SAL0139 in hyperlipidemia, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Started Aug 2026; status: active.
02
Drugs
SAL0139
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on CTR20262644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262644.